Sinovac vaccine to expand annual production capacity
Share - WeChat
BEIJING -- The third production line of CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac Biotech, was completed and put into production on Thursday. It will likely expand the company's annual production capacity to 2 billion doses.
As of Thursday, more than 200 million doses of CoronaVac, including the semi-finished ones, have been delivered to about 27 countries and regions, including China. More than 100 million doses have been administered around the globe, the company said on Friday.
So far, the Sinovac vaccine has received emergency use approval or conditional marketing authorization from more than 30 countries, the company said.
- Interest in Turkiye soars among Chinese tourists after introduction of visa-free entry
- Yunnan e-bike fire probe identifies raft of failings
- Investigation report released on e-bike fire that killed 8 in Southwest China
- Understanding Xi's vision of China and the world through New Year message
- 'Artificial sun' experiment finds way to break plasma density limit
- China reports 20% rise in inter-regional trips on first day of holiday

































